Pentokey Organy India Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Pentokey Organy (India) Ltd is ₹ 41.07 as of 06 May 15:30 . The P/E Ratio of Pentokey Organy (India) Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Pentokey Organy (India) Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Pentokey Organy (India) Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Pentokey Organy (India) Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Pentokey Organy (India) Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Pentokey Organy (India) Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Pentokey Organy (India) Ltd

Pentokey Organy (India) Ltd was incorporated on November 26, 1986.
The Company is engaged in the trading of Pharmaceutical products such as Acetic Acid, Ethyl Acetate and Acetaldehyde.
Ethyl Acetate is preferred by customers in all markets as it is fast replacing the petroleum-based solvents such as Toluene, MEK (Methyl Ethyl Ketone), MIBK (Methyl Iso Butyl Ketone) etc. In 2012-13, the production of intermediate product namely Acetic Acid was not competitive due to market prices.
Company therefore purchased the Acetic Acid from market instead of producing the same from Ethanol or Acetaldehyde.
As a result of this, production of Acetaldehyde, which is an intermediate product for Acetic Acid, was low.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Pentokey Organy (India) Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Pentokey Organy (India) Ltd or Sanofi India Ltd?

Market cap of Pentokey Organy (India) Ltd is 25 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Pentokey Organy (India) Ltd and Sanofi India Ltd?

The stock performance of Pentokey Organy (India) Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Pentokey Organy (India) Ltd and Sanofi India Ltd?

As of May 6, 2026, the Pentokey Organy (India) Ltd stock price is INR ₹41.07. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Pentokey Organy (India) Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Pentokey Organy (India) Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.